A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis
← catalyst calendarNCT06975722 · readout in 120 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
99estimated
Sites
67
Countries
Australia, China, Czechia +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-07 | actual | When the study began enrolling |
| Primary completion | 2026-12-17 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-10-17 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Ulcerative Colitis
Interventions
- Drug: SAR442970
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFProportion of participants who achieve clinical remission at the end of Week 16 by modified Mayo Score (mMS)
measured At Week 16
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed